Sun Pharma, India’s largest pharmaceutical company, is poised to acquire Checkpoint Therapeutics for $355 million. This strategic move is set to bolster Sun Pharma’s specialty portfolio, particularly with the addition of UNLOXCYT, an FDA-approved treatment for advanced skin cancer. This acquisition will not only strengthen Sun Pharma’s position in the global market for oncology treatments but also enhance its overall presence in the pharmaceutical industry. The deal is expected to bring about significant developments for Sun Pharma and further solidify its reputation as a key player in the healthcare sector.